A Phase 1 interventional study of Fluconazole and Fluconazole in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in Canada. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-19.
Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment
The objective of this study was an open-label, randomized, 2-way crossover to compare the single-dose relative bioavailability of Dr. Reddy's Laboratories, Ltd. and Pfizer (Diflucan®) 200 mg fluconazole tablets under fasting conditions.
Detailed Description : The study was conducted as an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 18 healthy adult male volunteers. A total of 17 subjects completed the clinical phase of the study. In each period, subjects were housed from the morning dosing until after the 72-hour blood draw. Single oral 200 mg doses were separated by a washout period of 21 days.
Dr. Reddy's Laboratories Limited is the lead sponsor of 220 studies on the registry; 2 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
History or presence of significant:
In addition, history or presence of:
Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 28 days prior to first dose.
Subjects who have been on an abnormal diet (for whatever reason) during the 28 days prior to the first dosing.
Subjects who, through completion of the study, would have donated in excess of:
Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
Drug: Fluconazole
Diflucan 200 mg fluconazole tablets of Pfizer
Drug: Fluconazole
Fluconazole Tablets, 200 mg
Also known as: Dr. Reddy's Laboratories
Fluconazole 200 mg tablets
Also known as: Diflucan (Pfizer)
Area Under Curve (AUC)
Time frame: pre dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5,4, 6, 9, 12, 24, 48 and 72 hours post-dose.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Reddy's Laboratories Limited